Sandoz invests $183M in European antibiotic production expansion

Sandoz, a division of Novartis, will invest more than $122 million to add new technology at its Kundl, Austria plant to make oral amoxicillin API, and $61 million into its Palafolls site in Spain to increase penicillin production capacity. Production at the Les Franqueses site will be phased out by 2024.

“Sandoz will shuffle its antibiotic production in Europe by adding capabilities at two of its plants and phasing out manufacturing at another by 2024, the company said.”endpoints.news

• 1 source
• endpoints.newsNovartis’ Sandoz reshuffles antibiotic supply chain in EU as field faces a shortage of investmentJosh SullivanMay 20, 2021

Summarized from public sources; check the original articles before acting on it.